European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2026
Optimizing venous thromboembolism prophylaxis timing in ventilated traumatic brain injury patients: a retrospective cohort study using ACS-TQIP data (2017-2021).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rhodes-Lyons Heather X, Elkbuli Adel, Nasef Hazem, Espat Nikita Nunes, Berg Gina, Johnson Sarah E, Rahm Jordan, McClure David L, Hunt Darrell, Sliter Joseph R, Martinek Lucy, Pepe Antonio
Аннотация
BACKGROUND: Traumatic brain injury (TBI) patients requiring mechanical ventilation face a heightened risk of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). While early VTE prophylaxis (VTEp) has been shown to reduce thromboembolic complications, the optimal timing remains unclear, particularly in ventilated TBI patients, where concerns about intracranial hemorrhage progression exist. This study evaluates the association between VTEp timing and mechanical ventilation duration in TBI patients.
METHODS: A retrospective cohort study was conducted using the American College of Surgeons Trauma Quality Program Participant Use File (ACS-TQIP-PUF) 2017-2021. Adult patients (≥ 15 years) with isolated TBI requiring mechanical ventilation were included. Patients were stratified by Modified Berne-Norwood Criteria (mBNC) into low, moderate, and high-risk categories for hemorrhagic progression. VTEp timing was categorized as very early (≤ 24 h), middle (24-72 h), and late (≥ 72 h). The primary outcome was the duration of mechanical ventilation, analyzed using multivariable linear regression models.
RESULTS: Among 99,078 patients, very early VTEp was associated with a reduction of 3.7 days in ventilator duration and in low and 2.8 days in moderate-risk TBI patients (p < .01). High-risk patients receiving very early prophylaxis exhibited increased mortality (21.3% p < .01).
CONCLUSION: Very early VTEp (≤ 24 h) was associated with a reduction of 3.7 ventilator days in low-risk and 2.8 days in moderate-risk TBI patients, while high-risk patients demonstrated increased mortality (21.3%). These findings underscore the importance of personalized, risk-stratified prophylaxis strategies. However, given the retrospective design and absence of radiologic progression or cause-specific mortality data, prospective validation is required before implementing practice modifications.
LEVELS OF EVIDENCE: Level III, retrospective/epidemiological.
METHODS: A retrospective cohort study was conducted using the American College of Surgeons Trauma Quality Program Participant Use File (ACS-TQIP-PUF) 2017-2021. Adult patients (≥ 15 years) with isolated TBI requiring mechanical ventilation were included. Patients were stratified by Modified Berne-Norwood Criteria (mBNC) into low, moderate, and high-risk categories for hemorrhagic progression. VTEp timing was categorized as very early (≤ 24 h), middle (24-72 h), and late (≥ 72 h). The primary outcome was the duration of mechanical ventilation, analyzed using multivariable linear regression models.
RESULTS: Among 99,078 patients, very early VTEp was associated with a reduction of 3.7 days in ventilator duration and in low and 2.8 days in moderate-risk TBI patients (p < .01). High-risk patients receiving very early prophylaxis exhibited increased mortality (21.3% p < .01).
CONCLUSION: Very early VTEp (≤ 24 h) was associated with a reduction of 3.7 ventilator days in low-risk and 2.8 days in moderate-risk TBI patients, while high-risk patients demonstrated increased mortality (21.3%). These findings underscore the importance of personalized, risk-stratified prophylaxis strategies. However, given the retrospective design and absence of radiologic progression or cause-specific mortality data, prospective validation is required before implementing practice modifications.
LEVELS OF EVIDENCE: Level III, retrospective/epidemiological.